Stem definition | Drug id | CAS RN |
---|---|---|
antivirals RNA polymerase (NS5B) inhibitors | 4914 | 1132935-63-7 |
Dose | Unit | Route |
---|---|---|
0.50 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
Vd (Volume of distribution) | 2.13 L/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 5.70 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 20, 2014 | EMA | AbbVie Ltd | |
Dec. 19, 2014 | FDA | ABBVIE INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Jaundice | 505.83 | 22.88 | 188 | 7695 | 28657 | 46649522 |
Blood bilirubin increased | 365.52 | 22.88 | 156 | 7727 | 34028 | 46644151 |
Hyperbilirubinaemia | 355.54 | 22.88 | 112 | 7771 | 10326 | 46667853 |
Hepatic failure | 271.92 | 22.88 | 126 | 7757 | 33290 | 46644889 |
Ascites | 210.73 | 22.88 | 109 | 7774 | 36475 | 46641704 |
Hepatic encephalopathy | 144.62 | 22.88 | 57 | 7826 | 10100 | 46668079 |
Hepatocellular carcinoma | 141.99 | 22.88 | 41 | 7842 | 2798 | 46675381 |
Hepatic cirrhosis | 133.04 | 22.88 | 61 | 7822 | 15671 | 46662508 |
Asthenia | 95.27 | 22.88 | 180 | 7703 | 310895 | 46367284 |
Anaemia | 88.35 | 22.88 | 156 | 7727 | 255623 | 46422556 |
Vomiting | 81.85 | 22.88 | 212 | 7671 | 452582 | 46225597 |
Nausea | 79.91 | 22.88 | 275 | 7608 | 687179 | 45991000 |
Drug ineffective | 69.61 | 22.88 | 15 | 7868 | 677823 | 46000356 |
Pruritus | 68.84 | 22.88 | 136 | 7747 | 242216 | 46435963 |
Yellow skin | 61.37 | 22.88 | 20 | 7863 | 2044 | 46676135 |
Haemoglobin decreased | 61.23 | 22.88 | 91 | 7792 | 128858 | 46549321 |
Child-Pugh-Turcotte score increased | 60.02 | 22.88 | 10 | 7873 | 44 | 46678135 |
Ocular icterus | 57.36 | 22.88 | 22 | 7861 | 3618 | 46674561 |
Renal impairment | 56.25 | 22.88 | 66 | 7817 | 74306 | 46603873 |
Bilirubin conjugated increased | 56.12 | 22.88 | 20 | 7863 | 2678 | 46675501 |
Chromaturia | 49.19 | 22.88 | 31 | 7852 | 14988 | 46663191 |
Fatigue | 44.30 | 22.88 | 211 | 7672 | 608486 | 46069693 |
Hepatorenal syndrome | 43.74 | 22.88 | 15 | 7868 | 1793 | 46676386 |
Encephalopathy | 41.94 | 22.88 | 39 | 7844 | 33550 | 46644629 |
Varices oesophageal | 40.73 | 22.88 | 16 | 7867 | 2803 | 46675376 |
Decreased appetite | 40.29 | 22.88 | 96 | 7787 | 193740 | 46484439 |
Portal vein thrombosis | 39.19 | 22.88 | 15 | 7868 | 2452 | 46675727 |
Oesophageal varices haemorrhage | 36.96 | 22.88 | 12 | 7871 | 1211 | 46676968 |
Off label use | 35.74 | 22.88 | 10 | 7873 | 379831 | 46298348 |
Upper gastrointestinal haemorrhage | 34.56 | 22.88 | 26 | 7857 | 16712 | 46661467 |
Acute hepatic failure | 32.94 | 22.88 | 24 | 7859 | 14697 | 46663482 |
Hepatic cancer | 32.56 | 22.88 | 14 | 7869 | 3083 | 46675096 |
Blood bilirubin unconjugated increased | 30.47 | 22.88 | 8 | 7875 | 382 | 46677797 |
Insomnia | 30.35 | 22.88 | 78 | 7805 | 164846 | 46513333 |
Hepatitis C | 28.41 | 22.88 | 16 | 7867 | 6302 | 46671877 |
Renal failure | 27.71 | 22.88 | 60 | 7823 | 113534 | 46564645 |
Pain | 26.49 | 22.88 | 25 | 7858 | 476923 | 46201256 |
Drug hypersensitivity | 25.71 | 22.88 | 5 | 7878 | 243820 | 46434359 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Blood bilirubin increased | 339.32 | 21.80 | 179 | 8481 | 36457 | 29907361 |
Jaundice | 243.21 | 21.80 | 138 | 8522 | 32348 | 29911470 |
Ascites | 230.31 | 21.80 | 138 | 8522 | 35783 | 29908035 |
Hepatocellular carcinoma | 195.31 | 21.80 | 81 | 8579 | 9529 | 29934289 |
Hepatic cirrhosis | 188.16 | 21.80 | 92 | 8568 | 15907 | 29927911 |
Hepatic failure | 188.13 | 21.80 | 119 | 8541 | 33924 | 29909894 |
Hyperbilirubinaemia | 148.68 | 21.80 | 80 | 8580 | 16862 | 29926956 |
Hepatic encephalopathy | 144.42 | 21.80 | 74 | 8586 | 14118 | 29929700 |
Renal impairment | 123.06 | 21.80 | 136 | 8524 | 84048 | 29859770 |
Fatigue | 95.20 | 21.80 | 253 | 8407 | 320420 | 29623398 |
Yellow skin | 64.97 | 21.80 | 24 | 8636 | 2069 | 29941749 |
Anaemia | 60.29 | 21.80 | 163 | 8497 | 207829 | 29735989 |
Ocular icterus | 59.42 | 21.80 | 25 | 8635 | 3039 | 29940779 |
Hepatitis C | 55.52 | 21.80 | 39 | 8621 | 13166 | 29930652 |
Encephalopathy | 53.91 | 21.80 | 56 | 8604 | 32149 | 29911669 |
Oesophageal varices haemorrhage | 52.91 | 21.80 | 23 | 8637 | 3028 | 29940790 |
Asthenia | 51.17 | 21.80 | 160 | 8500 | 221130 | 29722688 |
Blood bilirubin unconjugated increased | 50.10 | 21.80 | 15 | 8645 | 671 | 29943147 |
Haemoglobin decreased | 49.86 | 21.80 | 105 | 8555 | 113993 | 29829825 |
Portal hypertension | 47.66 | 21.80 | 23 | 8637 | 3850 | 29939968 |
Drug interaction | 44.91 | 21.80 | 143 | 8517 | 199425 | 29744393 |
Insomnia | 44.42 | 21.80 | 89 | 8571 | 93247 | 29850571 |
Distributive shock | 42.35 | 21.80 | 13 | 8647 | 633 | 29943185 |
Hepatitis C RNULL increased | 39.84 | 21.80 | 11 | 8649 | 367 | 29943451 |
Gastric varices haemorrhage | 39.14 | 21.80 | 10 | 8650 | 246 | 29943572 |
Alanine aminotransferase increased | 35.52 | 21.80 | 71 | 8589 | 74205 | 29869613 |
Child-Pugh-Turcotte score increased | 34.05 | 21.80 | 7 | 8653 | 62 | 29943756 |
Bilirubin conjugated increased | 32.69 | 21.80 | 17 | 8643 | 3334 | 29940484 |
Vomiting | 29.05 | 21.80 | 133 | 8527 | 219685 | 29724133 |
Nausea | 27.70 | 21.80 | 163 | 8497 | 296794 | 29647024 |
Chromaturia | 26.65 | 21.80 | 26 | 8634 | 13839 | 29929979 |
Varices oesophageal | 26.43 | 21.80 | 15 | 8645 | 3494 | 29940324 |
Hepatic lesion | 25.24 | 21.80 | 14 | 8646 | 3122 | 29940696 |
Alpha 1 foetoprotein increased | 25.17 | 21.80 | 9 | 8651 | 706 | 29943112 |
Immunosuppressant drug level increased | 24.82 | 21.80 | 16 | 8644 | 4686 | 29939132 |
Acute on chronic liver failure | 24.34 | 21.80 | 6 | 8654 | 127 | 29943691 |
Death | 23.72 | 21.80 | 42 | 8618 | 357241 | 29586577 |
Drug ineffective | 23.52 | 21.80 | 39 | 8621 | 340348 | 29603470 |
Irritability | 23.35 | 21.80 | 31 | 8629 | 23019 | 29920799 |
Arteriovenous malformation | 22.61 | 21.80 | 8 | 8652 | 609 | 29943209 |
Hepatorenal syndrome | 22.40 | 21.80 | 12 | 8648 | 2499 | 29941319 |
Headache | 22.36 | 21.80 | 108 | 8552 | 182198 | 29761620 |
Source | Code | Description |
---|---|---|
ATC | J05AP09 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections |
ATC | J05AP52 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections |
FDA MoA | N0000190113 | Breast Cancer Resistance Protein Inhibitors |
FDA EPC | N0000191257 | Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor |
FDA MoA | N0000191258 | RNULL Replicase Inhibitors |
FDA MoA | N0000191272 | UGT1A1 Inhibitors |
CHEBI has role | CHEBI:36044 | anti-virus drug |
CHEBI has role | CHEBI:85180 | nonstructural protein 5b inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic hepatitis C | indication | 128302006 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.38 | acidic |
pKa2 | 9.01 | acidic |
None
None
None
ID | Source |
---|---|
D10553 | KEGG_DRUG |
1456607-55-8 | SECONDARY_CAS_RN |
4034028 | VANDF |
C3850285 | UMLSCUI |
CHEBI:85182 | CHEBI |
CHEMBL3137312 | ChEMBL_ID |
56640146 | PUBCHEM_CID |
CHEMBL3544985 | ChEMBL_ID |
DB09183 | DRUGBANK_ID |
C588260 | MESH_SUPPLEMENTAL_RECORD_UI |
11270 | IUPHAR_LIGAND_ID |
9741 | INN_ID |
DE54EQW8T1 | UNII |
1597381 | RXNORM |
30778 | MMSL |
31899 | MMSL |
d08322 | MMSL |
015829 | NDDF |
015830 | NDDF |
714104000 | SNOMEDCT_US |
714105004 | SNOMEDCT_US |
716018007 | SNOMEDCT_US |
725851005 | SNOMEDCT_US |
None